← Back to Search

Vasodilator

PAH Therapies for Pulmonary Arterial Hypertension (CARE PAH Trial)

Phase 4
Waitlist Available
Research Sponsored by Actelion
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 years
Awards & highlights

Summary

This trial collects real-world data on people with pulmonary arterial hypertension (PAH) to understand their condition, treatments, and health outcomes better.

Eligible Conditions
  • Pulmonary Arterial Hypertension

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Time to Death due to Pulmonary Arterial Hypertension (PAH) or First Hospitalization due to PAH
Time to all Cause Death
Secondary study objectives
Change from Baseline in 6-minute Walk Distance (6MWD)
Change from Baseline in Health Related Quality of Life Assessed by European Quality of Life (EuroQoL) Group, 5-Dimension, 5-Level Questionnaire (EQ-5D-5L)
Change from Baseline in Health-Related Quality of life Status as Assessed by 36-item Short-Form Health Survey (SF-36) v2 Acute Questionnaire
+23 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Participants with PAHExperimental Treatment1 Intervention
Participants with pulmonary arterial hypertension (PAH) who newly initiate any PAH therapy(ies) at the index date (date when a participant starts the first new PAH therapy after baseline assessments) in a routine clinical setting, either as first-line therapy, as replacement therapies, as concomitant with other PAH therapies, or have already been receiving macitentan 10 milligrams (mg) for at least 3 months prior to the index date. The primary data source for this study will be the medical records of each participant.

Find a Location

Who is running the clinical trial?

ActelionLead Sponsor
191 Previous Clinical Trials
35,432 Total Patients Enrolled
66 Trials studying Pulmonary Arterial Hypertension
15,724 Patients Enrolled for Pulmonary Arterial Hypertension
Actelion Clinical TrialStudy DirectorActelion
13 Previous Clinical Trials
799 Total Patients Enrolled
2 Trials studying Pulmonary Arterial Hypertension
147 Patients Enrolled for Pulmonary Arterial Hypertension
~59 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top